公开(公告)号：WO2011118957A3

公开(公告)日：2012-01-12

申请号：PCT/KR2011001951

申请日：2011-03-22

Applicant: IUCF HYU ,  LEE SANG-KYUNG ,  YOU YOUNG-JIN ,  CHOI HYO-SUNG ,  PARK MIN-YOUNG

Inventor： LEE SANG-KYUNG ,  YOU YOUNG-JIN ,  CHOI HYO-SUNG ,  PARK MIN-YOUNG

IPC: A61K36/81 ,  A61K36/67 ,  A61P11/06 ,  A61P29/00 ,  A61P37/08

CPC classification number: A61K36/81

Abstract: The present invention relates to a composition which contains paprika extracts as active ingredients, and more particularly, to a pharmaceutical composition and to a functional health food for the prevention and treatment of inflammatory, allergic or asthma diseases, containing paprika extracts. Particularly, paprika is easily obtainable food and is an herb medicine, and therefore it does not cause side effects even after prolonged consumption.

Abstract translation: 本发明涉及含有辣椒粉提取物作为活性成分的组合物，更具体地涉及药物组合物和用于预防和治疗含有辣椒粉提取物的炎性，过敏性或哮喘病的功能保健食品。 特别是辣椒粉容易获得的食物，是药草，因此即使长时间消耗也不会引起副作用。

公开(公告)号：WO2008092081A2

公开(公告)日：2008-07-31

申请号：PCT/US2008/052054

申请日：2008-01-25

Applicant: IMMUNE DISEASE INSTITUTE, INC. ,  SHANKAR, Premlata ,  LEE, Sang-kyung ,  SWAMY, Manju ,  KUMAR, Priti ,  WU, Haoquan ,  BAN, Hong-Seok

Inventor： SHANKAR, Premlata ,  LEE, Sang-kyung ,  SWAMY, Manju ,  KUMAR, Priti ,  WU, Haoquan ,  BAN, Hong-Seok

IPC: A61K48/00

CPC classification number: C12N15/111 ,  A61K48/00 ,  C12N15/1135 ,  C12N15/1136 ,  C12N15/1138 ,  C12N15/115 ,  C12N2310/14 ,  C12N2310/3513 ,  C12N2320/32

Abstract: The present invention provides a method of delivering RNA interference molecules to a cell or a cell in a subject, which comprises contacting the cell with a protein-double stranded RNA complex, the complex comprising the double stranded RNA segment containing a double stranded RNA of interest and a protein, the protein comprising (1) a targeting moiety, which will specifically bind to a site on a target cell, and (2) a binding moiety linked thereto, which will bind to the double stranded RNA, wherein the double stranded RNA segment is delivered to a cell and effects RNA interference of the target RNA in the cell.

Abstract translation: 本发明提供了将RNA干扰分子递送至受试者的细胞或细胞的方法，该方法包括使细胞与蛋白质双链RNA复合物接触，所述复合物包含含有目的双链RNA的双链RNA片段 和蛋白质，所述蛋白质包含（1）将特异性结合靶细胞上的位点的靶向部分，和（2）与所述双链RNA结合的与其连接的结合部分，其中所述双链RNA 片段被递送到细胞并且影响目标RNA在细胞中的RNA干扰。

公开(公告)号：WO2005013886A2

公开(公告)日：2005-02-17

申请号：PCT/US2003/034686

申请日：2003-10-30

Applicant: THE CENTER FOR BLOOD RESEARCH, INC. ,  LIEBERMAN, Judy ,  SHANKAR, Premlata ,  NARASIMHASWAMY, Manjunath ,  SONG, Erwei ,  LEE, Sang-Kyung ,  INCE, Nedim

Inventor： LIEBERMAN, Judy ,  SHANKAR, Premlata ,  NARASIMHASWAMY, Manjunath ,  SONG, Erwei ,  LEE, Sang-Kyung ,  INCE, Nedim

IPC: A61K

CPC classification number: C12N15/1136 ,  C12N15/1138 ,  C12N2310/111 ,  C12N2310/14 ,  C12N2310/53 ,  C12N2799/027

Abstract: The present invention is based, at least in part, on the discovery of compositions and methods useful in the modulation, e.g ., inhibition, of gene expression or protein activity. In particular, the present invention is based on novel RNA interfering agents, e.g ., siRNA molecules which target apoptosis-related genes or proinflammatory cytokines, and result in reduction, e.g ., prolonged reduction, of apoptosis-related gene expression or proinflammatory cytokine expression in cells. Inhibition of apoptosis­related gene expression or protein activity or proinflammatory cytokine expression or protein activity, e.g ., by the siRNAs of the invention, inhibits apoptosis-mediated diseases or disorders and proinflammatory cytokine mediated diseases or disorders, including, for example, transplant rejection, hepatitis, liver injury, sepsis, and cancer.

Abstract translation: 本发明至少部分地基于发现可用于调节，例如抑制基因表达或蛋白质活性的组合物和方法。 特别地，本发明基于新的RNA干扰剂，例如靶向凋亡相关基因或促炎细胞因子的siRNA分子，并导致细胞凋亡相关基因表达或促炎细胞因子表达的减少，例如延长的减少 。 抑制凋亡相关基因表达或蛋白质活性或促炎细胞因子表达或蛋白质活性，例如本发明的siRNA抑制凋亡介导的疾病或病症和促炎细胞因子介导的疾病或病症，包括例如移植排斥，肝炎， 肝损伤，败血症和癌症。

公开(公告)号：WO2010079979A3

公开(公告)日：2010-12-02

申请号：PCT/KR2010000105

申请日：2010-01-07

Applicant: TECHNO SEMICHEM CO LTD ,  JUNG JAE SUN ,  YUN SU HYONG ,  KIM MINCHAN ,  HAN SUNG WON ,  PARK YONG JOO ,  SHIN SU JUNG ,  SUNG KI WHAN ,  LEE SANG KYUNG

Inventor： JUNG JAE SUN ,  YUN SU HYONG ,  KIM MINCHAN ,  HAN SUNG WON ,  PARK YONG JOO ,  SHIN SU JUNG ,  SUNG KI WHAN ,  LEE SANG KYUNG

IPC: C07F7/30

CPC classification number: C07F7/30 ,  C07F7/003

Abstract: Provided is a germanium complex represented by Chemical Formula 1 wherein Y1 and Y2 are independently selected from R3, NR4R5 or OR6, and R1 through R6 independently represent (Ci-C7) alkyl. The provided germanium complex with an amidine derivative ligand is thermally stable, is highly volatile, and does not include halogen components. Therefore, it may be usefully used as a precursor to produce high-quality germanium thin film or germanium-containing compound thin film by metal organic chemical vapor deposition (MOCVD) or atomic layer deposition (ALD).

Abstract translation: 提供由化学式1表示的锗配合物，其中Y 1和Y 2独立地选自R 3，NR 4 R 5或OR 6，且R 1至R 6独立地表示（C 1 -C 7）烷基。 提供的具有脒衍生物配体的锗络合物是热稳定的，挥发性高，并且不包含卤素组分。 因此，它可以有用地用作通过金属有机化学气相沉积（MOCVD）或原子层沉积（ALD）生产高质量锗薄膜或含锗化合物薄膜的前体。

公开(公告)号：WO2010079979A2

公开(公告)日：2010-07-15

申请号：PCT/KR2010/000105

申请日：2010-01-07

Applicant: TECHNO SEMICHEM, CO., LTD. ,  JUNG, Jae Sun ,  YUN, Su hyong ,  KIM, Minchan ,  HAN, Sung Won ,  PARK, Yong Joo ,  SHIN, Su Jung ,  SUNG, Ki whan ,  LEE, Sang Kyung

Inventor： JUNG, Jae Sun ,  YUN, Su hyong ,  KIM, Minchan ,  HAN, Sung Won ,  PARK, Yong Joo ,  SHIN, Su Jung ,  SUNG, Ki whan ,  LEE, Sang Kyung

IPC: C07F7/30

CPC classification number: C07F7/30 ,  C07F7/003

Abstract: Provided is a germanium complex represented by Chemical Formula 1 wherein Y1 and Y2 are independently selected from R3, NR4R5 or OR6, and R1 through R6 independently represent (Ci-C7) alkyl. The provided germanium complex with an amidine derivative ligand is thermally stable, is highly volatile, and does not include halogen components. Therefore, it may be usefully used as a precursor to produce high-quality germanium thin film or germanium-containing compound thin film by metal organic chemical vapor deposition (MOCVD) or atomic layer deposition (ALD).

Abstract translation: 提供了由化学式1表示的锗络合物，其中Y 1和Y 2独立地选自R 3，NR 4 R 5或OR 6，并且R 1至R 6独立地表示（C 1 -C 7）烷基。 提供的具有脒衍生物配体的锗络合物是热稳定的，是高挥发性的，并且不包括卤素组分。 因此，通过金属有机化学气相沉积（MOCVD）或原子层沉积（ALD）可有效地用作生产高品质锗薄膜或含锗化合物薄膜的前体。

公开(公告)号：WO2004039957A3

公开(公告)日：2004-09-30

申请号：PCT/US0334424

申请日：2003-10-29

Applicant: BLOOD RES CENTER ,  LIEBERMAN JUDY ,  SHANKAR PREMLATA ,  NARASIMHASWAMY MANJUNATH ,  SONG ERWEI ,  LEE SANG-KYUNG

Inventor： LIEBERMAN JUDY ,  SHANKAR PREMLATA ,  NARASIMHASWAMY MANJUNATH ,  SONG ERWEI ,  LEE SANG-KYUNG

IPC: A61K38/00 ,  C12N15/113 ,  A61K48/00 ,  C07H21/04 ,  C12Q1/68

CPC classification number: C12N15/1138 ,  A61K38/00 ,  A61M1/14 ,  A61M1/16 ,  A61M1/1609 ,  A61M1/1617 ,  A61M1/3406 ,  A61M1/3609 ,  A61M1/3612 ,  A61M2202/0498 ,  A61M2205/15 ,  A61M2205/33 ,  A61M2205/3317 ,  A61M2205/3324 ,  A61M2205/50 ,  A61M2205/52 ,  C12N15/1132 ,  C12N2310/111 ,  C12N2310/14 ,  C12N2310/53

Abstract: The present invention is based, at least in part, on the discovery of compositions and methods for the treatment and prevention of infectious diseases or disorders, e.g., HIV infection, AIDS, and AIDS-related diseases. In particular, the present invention pertains to methods of modulating cellular gene expression or protein activity, e.g., CCR5, gene expression or protein activity and/or gene expression or protein activity of a gene or sequence of an infectious agent, in order to treat or prevent infectious diseases or disorders, HIV infection, AIDS, or an AIDS-related disease or disorder. In one embodiment, the combination of an RNA interfering agent targeting a cellular gene in combination with an RNA interfering agent targeting a gene or sequence of an infectious agent results in prolonged prevention of infection by an infectious agent. The present invention is based on the identification of novel RNA interference agents, e.g., siRNA molecules, which target cellular genes, e.g., chemokine receptors, e.g., the CCR5 gene, and result in inhibition of target gene expression on target gene expressing cells, thereby inhibiting entry of infectious agents, e,g., HIV infection into target cells, prevention infection, and/or suppressing replication in established infection.

Abstract translation: 本发明至少部分基于发现用于治疗和预防感染性疾病或病症例如HIV感染，AIDS和AIDS相关疾病的组合物和方法。 具体而言，本发明涉及调节细胞基因表达或蛋白质活性（例如CCR5），基因表达或蛋白质活性和/或基因或感染因子序列的基因表达或蛋白质活性的方法，以治疗或 预防感染性疾病或病症，HIV感染，艾滋病或与AIDS相关的疾病或病症。 在一个实施方案中，靶向细胞基因的RNA干扰剂与靶向感染剂基因或序列的RNA干扰剂的组合导致延长的对传染因子感染的预防。 本发明基于鉴定靶向细胞基因（例如趋化因子受体，例如CCR5基因）的新型RNA干扰试剂例如siRNA分子，并且导致抑制靶基因表达细胞上的靶基因表达，由此 抑制感染因子例如HIV感染进入靶细胞，预防感染和/或抑制已建立的感染中的复制。

公开(公告)号：WO2004039957A2

公开(公告)日：2004-05-13

申请号：PCT/US2003/034424

申请日：2003-10-29

Applicant: THE CENTER FOR BLOOD RESEARCH, INC. ,  LIEBERMAN, Judy ,  SHANKAR, Premlata ,  NARASIMHASWAMY, Manjunath ,  SONG, Erwei ,  LEE, Sang-Kyung

Inventor： LIEBERMAN, Judy ,  SHANKAR, Premlata ,  NARASIMHASWAMY, Manjunath ,  SONG, Erwei ,  LEE, Sang-Kyung

IPC: C12N

CPC classification number: C12N15/1138 ,  A61K38/00 ,  A61M1/14 ,  A61M1/16 ,  A61M1/1609 ,  A61M1/1617 ,  A61M1/3406 ,  A61M1/3609 ,  A61M1/3612 ,  A61M2202/0498 ,  A61M2205/15 ,  A61M2205/33 ,  A61M2205/3317 ,  A61M2205/3324 ,  A61M2205/50 ,  A61M2205/52 ,  C12N15/1132 ,  C12N2310/111 ,  C12N2310/14 ,  C12N2310/53 ,  Y02A50/465

Abstract: The present invention is based, at least in part, on the discovery of compositions and methods for the treatment and prevention of infectious diseases or disorders, e.g., HIV infection, AIDS, and AIDS-related diseases. In particular, the present invention pertains to methods of modulating cellular gene expression or protein activity, e.g., CCR5, gene expression or protein activity and/or gene expression or protein activity of a gene or sequence of an infectious agent, in order to treat or prevent infectious diseases or disorders, HIV infection, AIDS, or an AIDS-related disease or disorder. In one embodiment, the combination of an RNA interfering agent targeting a cellular gene in combination with an RNA interfering agent targeting a gene or sequence of an infectious agent results in prolonged prevention of infection by an infectious agent. The present invention is based on the identification of novel RNA interference agents, e.g., siRNA molecules, which target cellular genes, e.g., chemokine receptors, e.g., the CCR5 gene, and result in inhibition of target gene expression on target gene expressing cells, thereby inhibiting entry of infectious agents, e,g., HIV infection into target cells, prevention infection, and/or suppressing replication in established infection.

Abstract translation: 本发明至少部分地基于发现用于治疗和预防感染性疾病或病症的组合物和方法，例如HIV感染，AIDS和AIDS相关疾病。 特别地，本发明涉及调节细胞基因表达或蛋白质活性的方法，例如CCR5，基因表达或蛋白质活性和/或感染因子的基因或序列的基因表达或蛋白质活性，以便治疗或 预防传染病或疾病，艾滋病毒感染，艾滋病或艾滋病相关疾病或病症。 在一个实施方案中，靶向细胞基因的RNA干扰剂与靶向感染因子的基因或序列的RNA干扰剂的组合导致长期预防感染因子的感染。 本发明基于鉴定靶向细胞基因（例如趋化因子受体，例如CCR5基因）的新型RNA干扰剂，例如siRNA分子，并导致靶基因表达细胞的靶基因表达的抑制，从而 抑制感染因子的侵入，例如艾滋病毒感染进入靶细胞，预防感染和/或抑制已知感染中的复制。

公开(公告)号：WO2008092081A8

公开(公告)日：2009-07-16

申请号：PCT/US2008052054

申请日：2008-01-25

Applicant: IMMUNE DISEASE INST INC ,  UNIV SOGANG IND UNIV COOP FOUN ,  SHANKAR PREMLATA ,  LEE SANG-KYUNG ,  SWAMY MANJU ,  KUMAR PRITI ,  WU HAOQUAN ,  BAN HONG-SEOK

Inventor： SHANKAR PREMLATA ,  LEE SANG-KYUNG ,  SWAMY MANJU ,  KUMAR PRITI ,  WU HAOQUAN ,  BAN HONG-SEOK

IPC: C12N15/11 ,  C12N15/113 ,  C12N15/115

CPC classification number: C12N15/111 ,  A61K48/00 ,  C12N15/1135 ,  C12N15/1136 ,  C12N15/1138 ,  C12N15/115 ,  C12N2310/14 ,  C12N2310/3513 ,  C12N2320/32

Abstract: The present invention provides a method of delivering RNA interference molecules to a cell or a cell in a subject, which comprises contacting the cell with a protein-double stranded RNA complex, the complex comprising the double stranded RNA segment containing a double stranded RNA of interest and a protein, the protein comprising (1) a targeting moiety, which will specifically bind to a site on a target cell, and (2) a binding moiety linked thereto, which will bind to the double stranded RNA, wherein the double stranded RNA segment is delivered to a cell and effects RNA interference of the target RNA in the cell.

Abstract translation: 本发明提供了将RNA干扰分子递送至受试者的细胞或细胞的方法，该方法包括使细胞与蛋白质双链RNA复合物接触，所述复合物包含含有目的双链RNA的双链RNA片段 和蛋白质，所述蛋白质包含（1）将特异性结合靶细胞上的位点的靶向部分，和（2）与所述双链RNA结合的与其连接的结合部分，其中所述双链RNA 片段被递送到细胞并且影响目标RNA在细胞中的RNA干扰。

公开(公告)号：WO2007044468A3

公开(公告)日：2007-09-13

申请号：PCT/US2006038980

申请日：2006-10-05

Applicant: CBR INST FOR BIOMED RES INC ,  SWAMY MANJUNATH N ,  SHANKAR PREMLATA ,  KUMAR PRITI ,  LEE SANG-KYUNG

Inventor： SWAMY MANJUNATH N ,  SHANKAR PREMLATA ,  KUMAR PRITI ,  LEE SANG-KYUNG

IPC: A61K48/00

CPC classification number: C12N15/1131 ,  C12N2310/111 ,  C12N2310/14 ,  C12N2310/53 ,  C12N2740/15043 ,  C12N2770/24111

Abstract: The present invention is directed to methods of treating flavivirus mediated diseases using siRNAs. The invention is based upon our findings in a mouse model that siRNAs directed against sequences conserved among multiple flaviviruses prevents and treats flavivirus infections. Accordingly, the present invention provides an isolated siRNA comprising a sense RNA and an antisense RNA strand or a single strand. The sense and the antisense RNA strands, or the single RNA strand, form an RNA duplex, and wherein the RNA strand comprises a nucleotide sequence identical to a target sequence of about 15 to about 30 contiguous nucleotides in flavivirus mRNA or mutant or variant thereof.

Abstract translation: 本发明涉及使用siRNA治疗黄病毒介导的疾病的方法。 本发明基于我们在小鼠模型中的发现，即针对多种黄病毒中保守序列的siRNA预防和治疗黄病毒感染。 因此，本发明提供了包含有义RNA和反义RNA链或单链的分离的siRNA。 正义和反义RNA链或单个RNA链形成RNA双链体，并且其中RNA链包含与黄病毒mRNA或其突变体或变体中的约15至约30个连续核苷酸的靶序列相同的核苷酸序列。

公开(公告)号：WO2005013886A3

公开(公告)日：2006-03-23

申请号：PCT/US0334686

申请日：2003-10-30

Applicant: BLOOD RES CENTER ,  LIEBERMAN JUDY ,  SHANKAR PREMLATA ,  NARASIMHASWAMY MANJUNATH ,  SONG ERWEI ,  LEE SANG-KYUNG ,  INCE NEDIM

Inventor： LIEBERMAN JUDY ,  SHANKAR PREMLATA ,  NARASIMHASWAMY MANJUNATH ,  SONG ERWEI ,  LEE SANG-KYUNG ,  INCE NEDIM

IPC: A61K48/00 ,  A61K20060101 ,  A61K31/00 ,  C07H21/04 ,  C12N15/113 ,  C12Q1/68

CPC classification number: C12N15/1136 ,  C12N15/1138 ,  C12N2310/111 ,  C12N2310/14 ,  C12N2310/53 ,  C12N2799/027

Abstract: The present invention is based, at least in part, on the discovery of compositions and methods useful in the modulation, e.g., inhibition, of gene expression or protein activity. In particular, the present invention is based on novel RNA interfering agents, e.g., siRNA molecules which target apoptosis-related genes or proinflammatory cytokines, and result in reduction, e.g., prolonged reduction, of apoptosis-related gene expression or proinflammatory cytokine expression in cells. Inhibition of apoptosis­related gene expression or protein activity or proinflammatory cytokine expression or protein activity, e.g., by the siRNAs of the invention, inhibits apoptosis-mediated diseases or disorders and proinflammatory cytokine mediated diseases or disorders, including, for example, transplant rejection, hepatitis, liver injury, sepsis, and cancer.

Abstract translation: 本发明至少部分地基于发现可用于调节，例如抑制基因表达或蛋白质活性的组合物和方法。 特别地，本发明基于新的RNA干扰剂，例如靶向凋亡相关基因或促炎细胞因子的siRNA分子，并导致细胞凋亡相关基因表达或促炎细胞因子表达的减少，例如延长的减少 。 抑制凋亡相关基因表达或蛋白质活性或促炎细胞因子表达或蛋白质活性，例如本发明的siRNA抑制凋亡介导的疾病或病症和促炎细胞因子介导的疾病或病症，包括例如移植排斥，肝炎， 肝损伤，败血症和癌症。